Supernus vs. Best Pharma Stocks
This is a news story, published by Yahoo Finance, that relates primarily to Supernus Pharmaceuticals news.
drug discoveries news
For more drug discoveries news, you can click here:
more drug discoveries newsYahoo Finance news
For more news from Yahoo Finance, you can click here:
more news from Yahoo FinanceAbout the Otherweb
Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
Chinese pharmaceutical firms. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest big pharmaceutical companies news, big American pharmaceutical corporations news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
Big Pharma acquisitionsInsider Trading & Hedge Fund Data, and Investment Newsletter From Insider Monkey
•Health
Health
Is Supernus Pharmaceuticals, Inc. (SUPN) the Best Pharma Stock to Buy for Long Term Growth?

80% Informative
Supernus Pharmaceuticals , Inc. (NASDAQ:SUPN) is a specialty company focused on developing and selling medications for central nervous system diseases, including epilepsy, migraine, and Parkinson’s disease.
About 30% of Big Pharma acquisitions involving at least $50 million upfront in 2024 involved Chinese corporations, according to DealForma statistics.
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) ranks 8th on our list of best pharma stocks to buy for long term growth.
In Q3 2024 , the company’s sales of the non-stimulant ADHD medication Qelbree increased by 68% to $62.4 million .
VR Score
80
Informative language
79
Neutral language
36
Article tone
semi-formal
Language
English
Language complexity
54
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
medium-lived
External references
6
Source diversity
1
Affiliate links
no affiliate links
Small business owner?